Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May;21(4):771-5.
doi: 10.1097/IGC.0b013e31821bb8aa.

Clinical trials in recurrent ovarian cancer

Michael Friedlander  1 , Edward Trimble, Anna Tinker, David Alberts, Elisabeth Avall-Lundqvist, Mark Brady, Philipp Harter, Sandro Pignata, Eric Pujade-Lauraine, Jalid Sehouli, Ignace Vergote, Philip Beale, Rudd Bekkers, Paula Calvert, Lawrence Copeland, Ros Glasspool, Antonio Gonzalez-Martin, Dionysis Katsaros, Jae Won Kim, Brigitte Miller, Diane Provencher, Lawrence Rubinstein, Mostafa Atri, Alain Zeimet, Monica Bacon, Henry Kitchener, Gavin C E Stuart; Gynecologic Cancer InterGroup
Affiliations
Free article
Review

Clinical trials in recurrent ovarian cancer

Michael Friedlander et al. Int J Gynecol Cancer. 2011 May.
Free article

Abstract

The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?

PubMed Disclaimer

Publication types